iMeds.se

Clozapine Actavis

Document: Clozapine Actavis tablet ENG PL change

Package leaflet: Information for the patient


Clozapine Actavis 25 mg tablets 100 mg tablets


clozapine


Read this leaflet carefully before you start using this medicine because it contains important information for you

- Keep this leaflet. You may need to read it again.

- If you have any further questions, ask your doctor or pharmacist.

- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.


What is in this leaflet

1. What is Clozapine Actavisand what is it used for

2. What you need to know before you take Clozapine Actavis

3. How to take Clozapine Actavis

4. Possible side effects

How to store Clozapine Actavis

Contents of the pack and other information


1. What Clozapine Actavis is and what it is used for


Clozapine Actavis belongs to a group of medicines called antipsychotics and exerts its effect on the central nervous system.

Clozapine Actavis is used to treat schizophrenia.

Clozapine Actavis can also be used for psychotic problems that has developed during treatment of Parkinson’s disease.


What you need to know before you take Clozapine Actavis


Before you start taking Clozapine Actavis a blood test will be taken to examine your blood and ensure whether you can be treated with Clozapine Actavis .

It is very important that you attend the blood tests that are needed once a week for the first 18 weeks of treatment. Thereafter a blood test is needed at least every fourth week as long as the treatment is ongoing and 4 weeks after the end of Clozapine Actavis treatment.

The blood tests are performed to check the amount of white blood cells (leukocytes and neutrophils) in your blood and minimise the risk of blood related side effects (decrease in the number of white blood cells).


Inform your doctor if you previously have taken Clozapine Actavis and had to stop treatment due to side effects of the blood.


Do not use Clozapine Actavis:

- if you have suffer from mental illness caused by alcohol, drugs or other poisoning.


If any of the above applies to you, tell your doctor and do not take Clozapine Actavis.

Clozapine Actavis must not be given to anyone who is unconscious or in a coma.


Warnings and precautions


Talk to your doctor or pharmacist before taking Clozapine Actavis

- if you or anyone in your family have previously had blood clots, as medicines like these have been associated with formation of blood clots.

- Clozapine Actavis can cause dry mouth, which can lead to an increased risk for dental caries.Brushing of the teeth twice a day with fluoride toothpaste is therefore recommended.

If patients treated with Clozapine Actavis get signs of fever, sore throat/pharynx/mouth or other signs of infection, they must contact a doctor immediately so that a blood test to exclude a reduction of white blood cells can be performed.

- contact your doctor if you plan to quit smoking since this might lead to an increase in side effects.

- if you are taking other antipsychotic medication.


Children and adolescents

The safety and efficacy of Clozapine Actavis in children and adolescents under the age of 16 years have not been established. It should not be used in this group until further data become available.


Other medicines and Clozapine Actavis

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

This especially applies to:

medicines suppressing the bone marrow (such as carbamazepine, chloramphenicol, phenylbutazone).

lithium.

- medicines used to treat depression (such as flucoxamine, fluoxetine, paroxetine, amitriptyline, chlorpramine.


Clozapine Actaviswith food, drink and alcohol

Do not drink alcohol during treatment with Clozapine Actavis since it enhances the negative effect of alcohol. You might need to contact your doctor if your caffeine drinking habits substantialy changes, so that your Clozapine Actavis dose can get adjusted.


Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.


The following symptoms may occur in newborn babies of mothers that have used Clozapine Actavis during the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.


Women should not breast-feed during treatment with Clozapine Actavis since the medicine may pass into the milk and affect the baby.


Your periods might return if you change from other antipsychotic medicinesto Clozapine Actavis. Therefore you should use effective contraception.


Driving and using machines

Clozapine Actavis causes tiredness and a lower seizure threshold. You should therefore not drive or operate machines during the first weeks of treatment.


Clozapine Actavis contains lactose monohydrate

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.


How to take Clozapine Actavis


Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.


The recommended dose for treatment-resistant schizophrenic patients is:

Adults

Starting dose 12.5 mg (one half of a 25 mg tablet) once or twice on the first day followed by 25 mg once or twice on the second day. If tolerated well, your doctor will then gradually increase the daily dose in steps of 25‑50 mg over the next 2‑3 weeks until a dose up to 300 mg per day is reached.


Elderly

A very low dose (a single dose of 12.5 mg the first day - one half of a 25 mg tablet) is recommended when initiating the treatment.


Maintenance dose

When the highest therapeutic effect is reached, many patients can maintain it with a lower dose.


The recommended dose for psychotic disturbances in patients with Parkinson’s disease is:

Adults

The effective daily dose is usually between 25 mg and 37.5 mg.


The usual starting dose is 12.5 mg (one half of a 25 mg tablet) in the evening. Continuous increases in the dose are normally done in steps of 12.5 mg, not faster than two steps a week, up to a maximum dose of 50 mg.


Treatment with Clozapine Actavis should continue for a longer period of time. Earlier symptoms can return if it is discontinued. Therefore it is important to take the tablets every day.


Contact your doctor or pharmacist if you experience the effect of Clozapine Actavis to be too strong or weak.


Duration of treatment

Your doctor will tell you the duration of treatment with Clozapine Actavis. You should not change the dose or treatment without talking to your doctor.


If you take more Clozapine Actavis than you should

If you have taken more Clozapine Actavis than recommended by your doctor, always contact your doctor or hospital.


The symptoms of overdose are drowsiness, confusion, hallucinations, seizures, twitching of arms and legs, blurred vision, low blood pressure, difficult breathing, fast heart rate and heartbeat (see section Possible Side Effect).


If you forget to take Clozapine Actavis

Contact your doctor if you forget to take Clozapine Actavis or if you have questions regarding the dosing. Do not take a double dose to make up for a forgotten dose.


If you stop taking Clozapine Actavis

The psychotic symptoms can re-occur if the treatment has to suddenly stop. The following reactions might also appear: such as excessive sweating, headache, nausea (feeling sick), vomiting (being sick) and diarrhea.


4. Possible side effects


Like all medicines, this medicine can cause side effects, although not everybody gets them.


Stop taking Clozapine Actavis and seek medical help immediately if you experience any of the following:

- Blood clotting - especially in the legs (symptoms are swelling, pain and reddening of the legs) and can be transported to the lungs and cause chest pain and difficulties in breathing. This is rare (may affect up to 1 in 1,000 people).

- Jaundice(yellowing of the skin or whites of the eyes) due to blocked bile duct. This is rare (may affect up to 1 in 1,000 people).

- Neuroleptic malignant syndrome(muscle stiffness, fever, impaired consciousness). This is uncommon (may affect up to 1 in 100 people).


Below is a list of other reported side effects.


Very common(may affect more than 1 in 10 people):

- Drowsiness, dizziness.

- Fast heartbeat.

- Constipation, increased production of saliva.


Common(may affect up to 1 in 10 people):

- Reduced level of white blood cells (granulocytes), elevated level of white blood cells.

- Weight gain.

- Blurred vision.

- Trembling, stiffness, restlessness, jerks, seizures, convulsions, muscle twitching.

- Changes in ECG, high blood pressure.

- Faintness or light-headedness after changing position, sudden loss of consciousness.

- Nausea (feeling sick), vomiting (being sick), loss of appetite, dry mouth.

- Loss of bladder control, difficulty in passing urine.

- Tiredness, fever, heat sensation, disturbances in sweating/temperature regulation.


Uncommon(may affect up to 1 in 100 people):

- Pronounced lack of white blood cells (granulocytes).


Rare(may affect up to 1 in 1,000 people):

- Diabetes which can cause weight loss, increased thirst, tiredness, restlessness, confusion, delirium.

- Difficulty in swallowing (e.g. food going down the wrong way), inflammation of the liver, inflammation of the pancreas.

- Cardiac arrhythmia, ECG changes associated with irregular heartbeats, cardiac arrest, inflammation of the heart muscle.


Very rare (may affect up to 1 in 10,000 people):

- Decrease in numbers of blood platelets, increase in numbers of blood platelets, very high blood sugar levels and increased acidity of the blood (ketoacidosis), increased levels of lipids in the blood, increased levels of cholesterol.

- Uncontrollable twitching of legs and arms.

- Disorder of the heart muscle.

- Enlargement of parotid glands.

- Severe liver and kidney damage.

- Skin reactions.

- Constipation, ileus.

- Persistent painful erection of the penis.


Not known(frequency cannot be estimated from the available data):

- In elderly people with dementia, a small increase in the number of people dying has been reported for patients taking antipsychotics compared with those not taking antipsychotics.

- Obsessive compulsive symptoms.


Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse.This includes any possible side effects not listed in this leaflet.You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


5. How to store Clozapine Actavis


Keep this medicine out of the sight and reach of children.


This medicinal product does not require any special storage conditions.


Do not use this medicine after the expiry date which is stated on the carton.


Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


6. Contents of the pack and other information


What Clozapine Actavis contains

The active substance is clozapine. Each tablet contains 25 mg. Each tablet contains 100 mg.

- The other ingredients are:lactose monohydrate, magnesium stearate, povidone, talc, maize starch, silica, colloidal anhydrous and pregelatinised starch.


What Clozapine Actavis looks like and contents of the pack



Marketing Authorisation Holder and Manufacturer


<[To be completed nationally]>

<[See Annex I - To be completed nationally]> [For referral procedures]


{Name and address}

<{tel}>

<{fax}>

<{e-mail}>


<This medicinal product is authorised in the Member States of the EEA under the following names:>


<{Name of the Member State}> <{Name of the medicinal product}>

<{Name of the Member State}> <{Name of the medicinal product}>


<[See Annex I - To be completed nationally]> [For referral procedures, as appropriate]


This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.


2016-07-28


6